Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71610-739

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-739). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 20 mg (71610 0739 74)

Label for Duloxetine Delayed-Release (DR) Capsules, USP 20 mg strength. The label indicates a package size of 500 capsules, with storage instructions to keep between 20-25 degrees Celsius, protect from light and moisture, and keep out of reach of children. Manufactured by GSMS, Inc. in Carrillo, CA, and repackaged by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine hydrochloride illustrating the molecular arrangement of atoms, including aromatic rings and functional groups distinctive to this active ingredient.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time from randomization to relapse (days). It compares Duloxetine delayed-release capsules to placebo, with Duloxetine represented by a solid line and placebo by a dashed line, indicating a lower relapse proportion for Duloxetine over the study period.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine delayed-release capsules and placebo treatments. The graph illustrates relapse rates up to approximately 275 days, with the placebo group showing a higher proportion of relapse than the Duloxetine group.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares multiple treatment groups, including Duloxetine 60 mg once daily, Duloxetine 60 mg twice daily, Duloxetine 20 mg once daily, and a placebo group. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), and Placebo, showing decreasing patient improvement as pain improvement percentage increases.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating patient pain improvement levels at various thresholds.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph comparing the percentage of patients with improved pain from baseline over time. The graph includes four lines representing Duloxetine delayed-release capsules at 20 mg, 60 mg, and 120 mg once daily doses, and a placebo group. The x-axis shows the percent improvement in pain from baseline, while the y-axis shows the percentage of patients reporting improvement.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved over time between placebo and Duloxetine Delayed-Release 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline, while the y-axis shows percentage of patients improved. Duloxetine demonstrates a higher percentage of patient improvement compared to placebo across the range.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline using BOCF method, showing two treatment groups: Placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine 60/120 mg once daily, with the Duloxetine group showing generally higher patient improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.